It has been observed that NSCLCs with inactivating mutations in LKB1 exhibit a poor response to anti-PD1 therapy despite a high tumor mutational burden (TMB) due to reduced expression of the immunoproteasome, impairing antigen presentation. The gene discussed is PDCD1; the disease is neoplasm.